Item 5.07. Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on June 2, 2026 (the “ Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below. As of the record date of the Annual Meeting, April 10, 2026, there were 82,911,783 shares of the Company’s common stock outstanding. Each share of common stock entitled its holder to one vote per share. The stockholders of the Company elected four Class I directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his or her successor has been duly elected and qualified, as follows: Director For Withheld Broker Non-Votes ──────────────────────────────────────────────────────────────────────────────────────────────────── Jessica Chutter 71,945,515 737,780 3,858,311 Matthew B. Klein, M. D., M. S., F. A. C. S. 71,550,878 1,132,417 3,858,311 Stephanie S. Okey, M. S. 68,902,707 3,780,588 3,858,311 Jerome B. Zeldis, M. D., Ph. D. 69,821,943 2,861,352 3,858,311 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “ For,” 355,794 votes “ Against,” and 15,520 votes “ Abstained.” The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “ For,” 1,492,801 votes “ Against,” 24,290 votes “ Abstained,” and 3,858,311 broker non-votes. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: June 5, 2026 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer